In order to evaluate the influence of thyroxine treatment on thyroid volume after thyroidectomy for non-toxic goitre 110 consecutive patients were randomised to receive thyroxine (150 [tg daily) or no treatment three months after operation.
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given to patients with diffuse non-toxic goitre suppresses thyroid volume by some 20 30%. 3 No such data are, however, available regarding the effect on other types of goitre or after thyroidectomy. Though the plasma thyroid stimulating hormone concentration is generally not raised in patients with non-specific goitre,4-8 prophylactic treatment should theoretically be useful, as suppressing thyroid stimulating hormone is believed to hinder goitrogenesis.
Reports on recurrence of goitre after thyroid resection are sparse,9-'2 and recently the influence of thyroxine given as prophylaxis has been questioned. 13 Other studies have had various shortcomings: they have been retrospective and non-randomised; follow up has been sporadic; and evaluation of the recurrence of goitre (by thyroid size or volume) has been performed by different clinicians using inaccurate methods-for example, palpation and scintiscan.
This study aimed at investigating thyroid volume (measured by ultrasonography'4) and thyroid function in a consecutive group of patients operated on for non-toxic goitre and randomised postoperatively to thyroxine treatment or no treatment.
Patients and methods
Three months after operation for non-toxic goitre 110 consecutive patients were allocated by random numbers' to receive 150 jig thyroxine daily or no treatment. An interval of three months was chosen because it allowed precise ultrasound evaluation of thyroid size not possible in the immediate postoperative period. Six and 12 months after operation thyroid volume and thyroid function were re-evaluated. Only a low degree of blindness could be achieved-that is, only the investigators performing the ultrasound scans were unaware of the study group to which patients had been allocated. All patients gave informed consent to the study. Five of the 52 patients randomised to receive thyroxine and three of the 58 randomised to no treatment had had a previous thyroidectomy. In a large non-goitrous group ofhealthy subjects we found that the thyroid volume ranged from roughly 9 to 28 ml (mean Thyroid stimulating hormone (mU/l)
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BRITISH MEDICAL JOURNAL VOLUME 294 28 MARCH 1987 18 ml (8-70 ml) three months after thyroidectomy to 16 ml (7-57 ml) at 12 months (p<0-01). A similar decrease in volume was seen in the group not given thyroxine-that is, from 20 (9-72) ml at three months to 17 (8-58) ml at 12 months (p<0-01; table III). A significant decrease in serum thyroid stimulating hormone and increase in serum thyroxine concentrations were found in the thyroxine treated patients, whereas these values were unchanged in the no treatment group. Serum triiodothyronine concentrations were unaltered in both groups (table  III) .
Three months after operation 14 patients subsequently randomised to no treatment had a raised serum thyroid stimulating hormone concentration (>3 3 mU/l). The median concentration in these patients was 5-4 mU/l (3 5-22-0 mU/l), and their median thyroid volume decreased from 17 (9-36) ml at three months to a median of 14 (9-29) ml 12 months postoperatively (p<0O02).
Three patients had recurrence of goitre within the observation period. Two of these were given thyroxine postoperatively, had unilateral resections, and had normal serum thyroid stimulating hormone concentrations postoperatively (0 4 and 0 7 mU/l). Their thyroid volumes at three, six, and 12 months were 29, 45, and 35 ml and 30, 51, and 57 ml, respectively. The other patient was not given thyroxine; she also had a unilateral resection and a normal serum thyroid stimulating hormone concentration postoperatively (2-7 mU/l), and her thyroid volumes were 23, 30, and 32 ml.
All 110 patients were followed up for one year after thyroidectomy, and there were no drop outs. Owing to symptoms of hyperthyroidism (tachycardia, weight loss, diarrhoea or loose stools, sweating, or nervousness) 14 of the 52 patients (27%) given thyroxine had their dose reduced to 100 [tg daily. There were no other side effects of thyroxine.
Discussion
This study found no significant difference in thyroid volume between the two groups one year after operation for non-toxic (table II) .
In the thyroxine treated group the median thyroid volume decreased from goitre. In addition, a similar decrease in thyroid volume from the third to 12th months was shown whether thyroxine was given or not. Furthermore, patients with raised sernm thyroid stimulating hormone values three months after operation and not randomised to thyroxine treatment had a significant fall in thyroid volume during the observation period. These findings and the fact that two of the three patients with recurrence of goitre received thyroxine post-. operatively question whether routine thyroxine is justifiable and whether standard thyroid function variables can identify those patients at risk of recurrence. Generally thyroid size is judged clinically by palpation, which is inexact and irreproducible. '6 In addition to a precise evaluation of thyroid size in our study, we defined recurrence using an objective measurement that avoided the confounding effect of a group of patients having enlarged thyroid glands postoperatively. Our results cannot be explained by differences between the two groups, as all the pretreatment data after operation were similar.
Despite the lack of controlled studies it has generally been recommended that these patients should be treated postoperatively with thyroxine in order to avoid recurrence.' The basis for this lies in the concept that increased concentrations of thyroid stimulating hormone are the main causal factor in the development and recurrence of non-toxic goitre. Hence it has been shown that both thyroxine and triiodothyronine treatment reduce thyroid volume in patients with diffuse goitre and that withdrawal is followed by subsequent regrowth.23 This volume reducing effect, however, has been recorded only in patients with diffuse goitre, and only a minority of patients operated on for non-toxic goitre (six of the 110 in this study) had a diffuse enlargement ofthe thyroid. Furthermore, finding serum thyroid stimulating hormone concentrations within the normal range in, patients with longstanding goitre" and recurrent non-toxic goitre8 casts doubt on the role of thyroid stimulating hormone in the genesis of goitre in man, though concentrations of the hormone may be raised in the early phase of goitre development.5' Hemithyroidectomy in rats was followed by hypertrophy of the remaining lobe'89 associated with increased serum thyroid stimulating hormone concentrations. 18 Clark et al, however, did not find basal concentrations of the hormone to be above normal in patients who had had hemithyroidectomy for unilateral lesions. '9 In accordance with this, Matte et al found a significant decrease in serum thyroxine and increase in serum thyroid stimulating hormone concentrations and an exaggerated response-of thyroid stimulating hormone to the releasing factor after hemithyroidectomy in euthyroid patients, but all changes occurred within the normal range and were transient.20 This may possibly explain why our study did not show significant changes in serum thyroxine and thyroid stimulating hormone concentrations in the patients not randomised to thyroxine after thyroidectomy, as these variables were not examined until three months postoperatively. We have no explanation for the decrease in thyroid volume from the third to 12th months in the group not given thyroxine, though conceivably serum thyroxine was decreased and serum thyroid stimulating hormone increased in the three months after operation, leading to compensatory hypertrophy of the thyroid. We have no data on changes in thyroid volume between the immediate postoperative period and the first three months. The very variable amounts of thyroid tissue left after thyroidectomy made it impossible to evaluate and compare this value with the one obtained by ultrasonography after three months.
Studies in snell dwarf mice lacking thyroid stimulating hormone have shown compensatory thyroid hyperplasia after hemithyroidectomy.21 Furthermore, studies in patients have shown no correlation between the rate of goitre enlargement and serum thyroid stimulating hormone concentrations, 22 suggesting that the regulation of thyroid growth in at least some conditions may be independent of the hormone.
Recent studies employing four separate methods have found circulating autoantibodies capable of stimulating thyroid growth selectively (thyroid growth stimulating immunoglobulins) in serum samples from patients with goitrous hyperthyroid Graves' disease.23-26 These autoantibodies have also been detected in the serum of patients with non-toxic goitre.2326 Van der Gaag et al found that values for thyroid growth stimulating immunoglobulins in euthyroid subjects tended to be high in diffuse goitre, nodular goitre recurring after partial thyroidectomy, and goitre with recent growth.27 A positive correlation between thyroid volume and thyroid growth stimulating immunoglobulins28 lends further support to the possibility of an immunological explanation for goitre formation. These results also show the complexity of the pathogenesis of goitre and underline the possibility suggested by Stider et al of large variations in the individual response to a goitrogen. '9 In conclusion, thyroid volume decreased during the first year after thyroidectomy for non-toxic goitre independently of thyroxine treatment. It therefore seems questionable whether postoperative thyroid function studies can identify patients at risk ofrecurrence of goitre and whether routine postoperative treatment with thyroxine is justifiable at all. Only further follow up of larger groups of patients will clarify whether the long term recurrence rate is influenced by postoperative thyroxine treatment.
